S-1 maintenance after chemoradiation for locally advanced esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a chemotherapy pill called S-1 given as maintenance therapy after completing chemoradiation for esophageal cancer. The goal is to see if taking S-1 for a longer time helps keep the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 20 years old.
- You have a certain type of esophageal cancer (squamous cell, adenocarcinoma, or at the junction between the esophagus and stomach).
- Your cancer is locally advanced (stage II to IVA) and has not spread to distant organs, and surgery is not part of your treatment plan.
- You have completed a full course of chemotherapy and radiation therapy (chemoradiation) as your main treatment, and your scans show that the cancer has not gotten worse.
- Your overall health is fairly good (able to care for yourself) and your major organs (like bone marrow, liver, kidneys, and heart) are working well enough, as determined by your doctor.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether taking an oral chemotherapy pill (S-1) after standard treatment can help keep pancreatic cancer from coming back in people who have a higher chance of recurrence. It compares that to just watching and waiting.
This Phase 3 study compares two ways of giving S-1 medicine after curative stomach cancer surgery in stage III disease. It aims to see whether the sequential approach improves outcomes while keeping treatment safe.
This trial tests whether adding a third drug (S-1, a chemotherapy pill) to the standard two-drug IV chemo (albumin-bound paclitaxel and gemcitabine) can help people with advanced pancreatic cancer live longer. It's for those who haven't had treatment yet for their advanced cancer.
This trial tests a combination of the immunotherapy drug tislelizumab and the chemotherapy drug S-1 for people with a specific type of esophageal cancer that still has some cancer cells in the main tumor but no cancer in lymph nodes after surgery. The goal is to see if this treatment can help prevent the cancer from coming back.
This trial tests if adding radiation before and after standard chemotherapy can help people whose esophageal cancer has come back after initial treatment. It aims to improve control of the cancer while keeping side effects manageable.
This trial tests a new combination of chemotherapy drugs and radiation for advanced esophageal cancer that cannot be removed with surgery. The goal is to see if this treatment can help shrink the cancer and improve outcomes.
Hear when a new Locally Advanced Unresectable Esophageal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.